WO2007036366A2 - Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen - Google Patents
Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen Download PDFInfo
- Publication number
- WO2007036366A2 WO2007036366A2 PCT/EP2006/009448 EP2006009448W WO2007036366A2 WO 2007036366 A2 WO2007036366 A2 WO 2007036366A2 EP 2006009448 W EP2006009448 W EP 2006009448W WO 2007036366 A2 WO2007036366 A2 WO 2007036366A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid sequence
- sequence
- transcript
- transcription
- Prior art date
Links
- 238000013519 translation Methods 0.000 title claims abstract description 60
- 230000001965 increasing effect Effects 0.000 title abstract description 22
- 230000004048 modification Effects 0.000 title abstract description 21
- 238000012986 modification Methods 0.000 title abstract description 21
- 238000000338 in vitro Methods 0.000 claims abstract description 51
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 391
- 239000002773 nucleotide Substances 0.000 claims description 191
- 125000003729 nucleotide group Chemical group 0.000 claims description 187
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 178
- 102000039446 nucleic acids Human genes 0.000 claims description 172
- 108020004707 nucleic acids Proteins 0.000 claims description 172
- 230000035897 transcription Effects 0.000 claims description 114
- 238000013518 transcription Methods 0.000 claims description 114
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 63
- 210000004443 dendritic cell Anatomy 0.000 claims description 49
- 238000003776 cleavage reaction Methods 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 43
- 230000007017 scission Effects 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 39
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 108091008146 restriction endonucleases Proteins 0.000 claims description 21
- 230000008878 coupling Effects 0.000 claims description 17
- 238000010168 coupling process Methods 0.000 claims description 17
- 238000005859 coupling reaction Methods 0.000 claims description 17
- 238000001890 transfection Methods 0.000 claims description 14
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 claims description 12
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 6
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 108060003196 globin Proteins 0.000 claims description 6
- 108700008625 Reporter Genes Proteins 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- 102100038803 Somatotropin Human genes 0.000 claims description 4
- 108010053584 alpha-Globins Proteins 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 102000018146 globin Human genes 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 102100031780 Endonuclease Human genes 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 claims 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 abstract description 5
- 229920002477 rna polymer Polymers 0.000 description 141
- 108091034057 RNA (poly(A)) Proteins 0.000 description 54
- 239000013598 vector Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 18
- 102000053602 DNA Human genes 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 12
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 11
- 108091023045 Untranslated Region Proteins 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000026279 RNA modification Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 108010075205 OVA-8 Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 244000058084 Aegle marmelos Species 0.000 description 2
- 235000003930 Aegle marmelos Nutrition 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000004678 Exoribonucleases Human genes 0.000 description 1
- 108010002700 Exoribonucleases Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000002480 thymidyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Definitions
- DNA-based vaccines against infectious pathogens were tested (Cox et al., 1993, Davis et al., 1993, Ulmer et al., 1993, Wang et al., 1993), but soon further explored in gene therapy against tumors to induce specific anti-tumor immunity (Conry et al., 1994, Conry et al., 1995a; Spooner et al., 1995; Wang et al., 1995).
- This strategy of tumor immunization has a number of key benefits.
- Nucleic acid based vaccines are easy to prepare and relatively inexpensive. They can also be amplified from a small cell count.
- RNA DNA is more stable than RNA, but has some potential safety risks, such as induction of anti-DNA antibodies (Gilkeson et al., 1995) and integration of the transgene into the host genome. This can lead to inactivation of cellular genes, uncontrollable long-term expression of the transgene or oncogenesis and is therefore tumor-associated antigens with oncogenic potential such as erb-B2 (Bargmann et al., 1986) and p53 (Greenblatt et al., 1994) Generally not applicable. To circumvent these potential dangers, the use of RNA offers an attractive alternative. Advantages of using RNA as a type of reversible gene therapy include transient expression and non-transforming character.
- RNA does not have to enter the nucleus to be transgenically expressed, nor can it integrate into the host genome, eliminating the risk of oncogenesis.
- DNA Condon et al., 1996; Tang et al., 1992
- both the cellular and humoral immune responses can be induced in vivo by the injection of RNA (Hoerr et al., 2000, Ying et al. 1999).
- IVT-RNA in vitro transcribed RNA
- RNA is directly injected via different immunization routes (Hoerr et al., 2000) or dendritic cells (DCs) are transfected by lipofection or electroporation with in vitro transcribed RNA and then applied (Heiser et al., 2000).
- immunization with RNA-transfected DCs induces antigen-specific cytotoxic T lymphocytes (CTL) in vitro and in vivo (Su et al., 2003; Heiser et al., 2002).
- CTL cytotoxic T lymphocytes
- the dose ie the density of the antigen presentation on the DCs, is of central importance for the optimal induction of the T cell-mediated immune responses.
- IVT vectors are known from the literature, which are used in a standardized manner as a template for in vitro transcription and have been genetically engineered to result in stabilized RNA transcripts. Protocols currently described in the literature (Conry et al., 1995b; Teufel et al., 2005; Strong et al., 1997; Carralot et al., 2004; Boczkowski et al., 2000) are based on a plasmid vector with the following Structure: a 5 'RNA polymerase promoter allowing transcription of RNA followed by a gene of interest containing either 3' and / or 5 'of untranslated regions (UTR).
- UTR 3' and / or 5 'of untranslated regions
- RNA seems to be particularly well suited for clinical applications.
- the use of RNA in gene therapy is severely restricted, in particular by the short half-life of RNA, in particular in the cytoplasm, which results in low protein expression.
- RNA with increased stability and translation efficiency and means for obtaining such RNA.
- increased expression levels should be achievable.
- the present invention relates to a stabilization of RNA, in particular mRNA, and an increase in the translation of mRNA. More particularly, the present invention relates to three modifications of RNA, particularly in vitro transcribed RNA, which result in increased transcript stability and translational efficiency.
- RNA with an open-ended poly (A) sequence is translated more efficiently than RNA with a covertly ending poly (A) sequence.
- a long poly (A) sequence particularly of about 120 bp, results in optimal transcript stability and translational efficiency of RNA.
- UTR double 3 'untranslated region
- Combination of the modifications described above has a synergistic effect on the stabilization of the RNA and the increase in translation.
- RNA modifications according to the invention independently enhance the RNA stability and translation efficiency in transfection of dendritic cells (DC).
- DC dendritic cells
- the invention therefore relates to a strategy for optimizing RNA-transfected DC vaccines by using RNA which has been modified by the RNA modifications described according to the invention.
- modification and thereby stabilization and / or enhancement of the translation efficiency of RNA are achieved by genetically modifying expression vectors which preferably serve as templates for the in vitro transcription of RNA.
- such vectors are intended to permit transcription of RNA with a poly (A) sequence, the poly (A) sequence preferably having an open end in the RNA, i. No nucleotides other than A nucleotides flank the poly (A) sequence at its 3 'end.
- An open ended poly (A) sequence in the RNA can be achieved by permitting into an expression vector which allows the transcription of RNA under the control of a 5 'RNA polymerase promoter and a
- Polyadenyl cassette (poly (A) sequence), a restriction cleavage site of type Hs is introduced, the recognition sequence being 3 'from the poly (A) sequence, while the upstream site lies within the poly (A) sequence.
- a plasmid By restriction cleavage at the restriction cleavage site of type IIS, a plasmid can be used to linearise the plasmid within the poly (A) sequence ( Figure 2). The linearized plasmid can then be used as a template for in vitro transcription, with the resulting transcript ending with an unprotected poly (A) sequence.
- a modification and thereby stabilization and / or enhancement of the translation efficiency of RNA can be achieved by genetically modifying expression vectors such that they inhibit the transcription of RNA with two or more 3 'untranslated regions at its 3' end. And preferably between the sequence coding for a peptide or protein (open reading frame) and the poly (A) sequence.
- the invention relates to a nucleic acid molecule comprising, in the 5 ' ⁇ 3' direction of transcription: (a) a promoter; (B) a transcribable nucleic acid sequence or a nucleic acid sequence for introducing a transcribable nucleic acid sequence; (c-1) a first nucleic acid sequence corresponding to or derived from the 3'-untranslated region of a gene; and (c-2) a second nucleic acid sequence corresponding to or derived from the 3'-untranslated region of a gene.
- the nucleic acid molecule according to the invention further comprises (c-3) at least one further nucleic acid sequence which corresponds to or is derived from the 3'-untranslated region of a gene.
- the nucleic acid sequences (b), (c-1), (c-2) and optionally (c-3) are preferably transcribable under control of the promoter (a) into a common transcript and in the common transcript are those of the nucleic acid sequences (c-1) and / or (c-2) and / or optionally (c-3) transcribed nucleic acid sequences preferably effective to increase the translation efficiency and / or stability of the transcribed nucleic acid sequence of the transcribable nucleic acid sequence (b).
- nucleic acid sequences (c-1), (c-2) and optionally (c-3) may be the same or different.
- the nucleic acid molecule further comprises (d) a nucleic acid sequence which, when transcribed under control of the promoter (a), encodes a nucleotide sequence of at least 20 consecutive A nucleotides in the transcript.
- the nucleic acid sequences (b), (c-1), (c-2), optionally (c-3), and (d) are preferably transcribable under the control of the promoter (a) into a common transcript and in the common transcript from the nucleic acid sequences (c-1) and / or (c-2) and / or optionally (c-3) and / or (d) transcribed nucleic acid sequences preferably effective, the translation efficiency and / or stability of the nucleic acid sequence from the transcribable (b ) to increase transcribed nucleic acid sequence.
- the nucleic acid sequence (d) encodes a nucleotide sequence of at least in a transcription under the control of the promoter (a) 40, preferably at least 80, preferably at least 100 and in particular about 120 consecutive A nucleotides in the transcript.
- the nucleic acid sequence (d) encodes a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200 and in particular up to 150 consecutive A nucleotides in the transcript.
- the nucleic acid molecule is characterized in that it is preferably enzymatically or otherwise biochemically cleavable within the nucleic acid sequence (d) in such a way that the cleavage produces a nucleic acid molecule which, in the 5 'to 3' direction of the transcription, forms the promoter (a).
- the nucleic acid molecule after cleavage at the end of the strand which serves as a template for the nucleotide sequence of at least 20 consecutive A-
- Nucleotides serve a T nucleotide that is part of the nucleotide sequence that serves as a template for the nucleotide sequence of at least 20 consecutive A nucleotides in the transcript.
- the at least part of the nucleic acid sequence (d) when transcribed under control of the promoter (a), the at least part of the nucleic acid sequence (d) encodes a nucleotide sequence of at least 40, preferably at least 80, preferably at least 100, and most preferably about 120 consecutive A nucleotides in the transcript.
- the nucleic acid sequence (d) encodes a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200 and in particular up to 150 consecutive A nucleotides in the transcript.
- the nucleic acid molecule according to the invention is preferably present before the cleavage as a circular closed molecule and after cleavage as a linear molecule.
- the cleavage is preferably carried out with the aid of a restriction cleavage site, the restriction cleavage site preferably being a restriction cleavage site for a restriction endonuclease of the IIS type.
- the recognition sequence for the restriction endonuclease of the type IIS in one embodiment is downstream and 5-26 base pairs, preferably 24-26 base pairs away from the 3 'end of the nucleic acid sequence (d).
- the nucleic acid sequences (c-1), (c-2) and optionally (c-3) are independently derived from a gene selected from the group consisting of globin genes such as alpha2 globin, alphal globin, beta globin, and growth hormone, preferably human beta globin, and in a particularly preferred embodiment correspond to the nucleic acid sequence of SEQ ID NO: 1 of the Sequence Listing or of a nucleic acid sequence derived therefrom.
- the invention relates to a nucleic acid molecule comprising, in the 5 ' ⁇ 3' direction of transcription: (a) a promoter; (b) a transcribable
- Nucleic acid sequence or a nucleic acid sequence for introducing a transcribable nucleic acid sequence and (c) a nucleic acid sequence which, when transcribed under control of the promoter (a), encodes a nucleotide sequence of at least 20 consecutive A nucleotides in the transcript.
- the nucleic acid sequences (b) and (c) are preferably transcribable under the control of the promoter (a) into a common transcript and in the common transcript the nucleic acid sequence transcribed from the nucleic acid sequence (c) is preferably effective, the translation efficiency and / or the stability of to increase the transcribed nucleic acid sequence (b) transcribed nucleic acid sequence.
- the nucleic acid sequence (c) upon transcription under control of the promoter (a), encodes a nucleotide sequence of at least 40, preferably at least 80, preferably at least 100 and in particular about 120 consecutive A nucleotides in the transcript.
- the nucleic acid sequence (c) encodes a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200 and in particular up to 150 consecutive A nucleotides in the transcript.
- the nucleic acid molecule is preferably enzymatically or otherwise biochemically cleavable within the nucleic acid sequence (c) in such a way that the cleavage produces a nucleic acid molecule which in the 5 'to 3' direction of the transcription comprises the promoter (a), the nucleic acid sequence (b). and at least part of
- the nucleic acid molecule comprises a T nucleotide which is part of the nucleotide sequence which serves as template for the nucleotide sequence of at least 20 consecutive following A nucleotides in the
- the at least part of the nucleic acid sequence (c) encodes a nucleotide sequence of at least 40, preferably at least 80, preferably at least 100, and most preferably about 120 consecutive A nucleotides in the transcript upon transcription under control of the promoter (a).
- the nucleic acid sequence (c) encodes a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200 and in particular up to 150 consecutive A nucleotides in the transcript.
- the nucleic acid molecule is preferably present before the cleavage as a circular closed molecule and after cleavage as a linear molecule.
- the cleavage is preferably carried out with the aid of a restriction cleavage site, the restriction cleavage site preferably being a restriction cleavage site for a restriction endonuclease of the IIS type.
- the recognition sequence for the restriction endonuclease of the type IIS is in one embodiment downstream and 5-26 base pairs, preferably 24-26 base pairs away from the 3 'end of the nucleic acid sequence (c).
- the transcribable nucleic acid sequence preferably comprises one coding for a peptide or protein
- Nucleic acid sequence and the nucleic acid sequence for introducing a transcribable nucleic acid sequence is preferably a multiple cloning site.
- a nucleic acid molecule of the invention may comprise one or more members selected from the group consisting of: (i) a reporter gene; (ii) a selectable marker; and (iii) an origin of replication.
- a nucleic acid molecule according to the invention is present in a circularly closed conformation and is preferably suitable, in particular after a linerization, for the in vitro transcription of RNA, in particular mRNA.
- the invention relates to a nucleic acid molecule obtainable by linearization of a nucleic acid molecule described above, preferably by cleavage within the nucleic acid sequence encoding a nucleotide sequence of at least 20 consecutive A nucleotides, and RNA obtained by transcription, preferably in FIG In vitro transcription, with nucleic acid molecules described above under control of the promoter (a) is available.
- the invention features a method of in vitro transcription of a selected RNA molecule to increase its stability and / or translation efficiency, comprising: (i) coupling a first nucleic acid sequence (b-1) corresponding to the 3 ' at the 3'-end of a nucleic acid sequence (a) transcribable into the RNA molecule, (ii) coupling a second nucleic acid sequence (b-2) corresponding to the 3'-end of a gene. untranslated region of a gene corresponding to or derived from, at the 3 'end of the first nucleic acid sequence (b-1), and (iii) in vitro transcription of the resulting nucleic acid.
- the invention relates to a method of translating a selected mRNA molecule to increase its expression, comprising: (i) coupling a first nucleic acid sequence (b-1) corresponding to the 3'-untranslated region of a gene or derived from, at the 3 'end of a nucleic acid sequence (a) transcribable into the mRNA molecule, (ii) coupling a second nucleic acid sequence (b-2) to the 3' untranslated region of a gene corresponding to or derived from, at the 3 'end of the first nucleic acid sequence (b-1), and (iii) translating the mRNA obtainable by transcription of the obtained nucleic acid.
- transcription is in vitro.
- the term "coupling a nucleic acid sequence to the 3 'end of a nucleic acid sequence” refers to a covalent linkage of the two nucleic acid sequences so that the first nucleic acid sequence is downstream of the second nucleic acid sequence and can be separated therefrom by additional nucleic acid sequences.
- the methods of the invention further comprise coupling at least one further nucleic acid sequence (b-3) corresponding to or derived from the 3 'untranslated region of a gene at the 3' end of the second nucleic acid sequence (b-2 ).
- the nucleic acid sequences (a), (b-1), (b-2) and optionally (b-3) are preferably transcribable into a common transcript and in the common transcript are those of the nucleic acid sequences (b-1) and / or ( b-2) and / or optionally (b-3) transcribed nucleic acid sequences preferably effective to increase the translation efficiency and / or the stability of the nucleic acid sequence transcribed from the nucleic acid sequence (a).
- the methods of the invention further comprise coupling a nucleic acid sequence (c) which, when transcribed, encodes a nucleotide sequence of at least 20 consecutive A nucleotides, at the 3 'end of the nucleic acid sequence (b-2) or optionally Nucleic acid sequence (b-3).
- nucleic acid sequences (a), (b-1), (b-2) and optionally (b-3), and (c) are preferably transcribable into a common transcript and in the common transcript are those of the nucleic acid sequences (b-1 ) and / or (b-2) and / or optionally (b-3) and / or (c) transcribed nucleic acid sequences are preferably effective to increase the translation efficiency and / or the stability of the nucleic acid sequence transcribed from the nucleic acid sequence (a).
- the nucleic acid sequence (c) upon transcription, encodes a nucleotide sequence of at least 40, preferably at least 80, preferably at least 100 and in particular about 120 consecutive A-
- nucleic acid sequence (c) encodes a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200, and most preferably up to 150 consecutive A nucleotides in the transcript.
- the methods according to the invention further comprise a cleavage within the nucleic acid sequence (c) prior to transcription of the nucleic acid obtained such that a transcription of the nucleic acid thus obtained generates a transcript corresponding to the nucleic acid sequences (a), (b-1 ), (b-2) and optionally (b-3) transcribed nucleic acid sequences and at its 3 'end a
- nucleotide sequence of at least 20 consecutive A nucleotides wherein the transcript has as 3 '-terminal nucleotide an A nucleotide from the nucleotide sequence of at least 20 consecutive A nucleotides.
- the transcript has one at its 3 'end
- the transcript has at its 3 'end a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200 and in particular up to 150 consecutive A nucleotides.
- the nucleic acid sequences (b-1), (b-2) and optionally (b-3) are independently preferably derived from a gene selected from the group consisting of globin genes such as alpha2 globin, alphal globin . beta globin, and growth hormone, preferably human beta globin, and in a particularly preferred embodiment correspond to the nucleic acid sequence of SEQ ID NO: 1 of the Sequence Listing or of a nucleic acid sequence derived therefrom.
- the invention relates to a method of in vitro transcription of a selected RNA molecule to increase its stability and / or translation efficiency, comprising: (i) coupling a nucleic acid sequence (b) that results from transcription for a nucleotide sequence of at least 20 consecutive A nucleotides encoded at the 3 'end of a nucleic acid sequence (a) transcribable in the RNA molecule, and (ii) in vitro transcription of the resulting nucleic acid.
- the invention features a method of translating a selected mRNA molecule to increase its expression, comprising: (i) coupling a nucleic acid sequence (b) that results from transcription for a nucleotide sequence of at least 20 consecutive A nucleotides coded at the 3 'end of a
- Nucleic acid sequence (a) transcribable in the mRNA molecule, and (ii) Translating the mRNA obtainable by transcription of the obtained nucleic acid. Transcription is preferably in vitro.
- the nucleic acid sequences (a) and (b) are preferably transcribable into a common transcript and in the common transcript the nucleic acid sequence transcribed from the nucleic acid sequence (b) is preferably effective, the translation efficiency and / or the stability of the nucleic acid sequence transcribed from the nucleic acid sequence (a) to increase.
- the nucleic acid sequence (b) upon transcription, encodes a nucleotide sequence of at least 40, preferably at least 80, preferably at least 100 and most preferably about 120 consecutive A nucleotides in the transcript.
- the nucleic acid sequence (b) upon transcription, encodes a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200, and most preferably up to 150 consecutive A nucleotides in the transcript.
- the methods according to the invention further comprise a cleavage within the nucleic acid sequence (b) prior to transcription of the nucleic acid obtained, such that upon transcription of the nucleic acid thus obtained a transcript is generated which comprises the nucleic acid sequences transcribed from the nucleic acid sequence (a) and at its 3 'end has a nucleotide sequence of at least 20 contiguous A nucleotides, the transcript having as a 3' -terminal nucleotide an A nucleotide from the nucleotide sequence of at least 20 contiguous A nucleotides.
- the transcript has one at its 3 'end
- the transcript has at its 3 'end a nucleotide sequence of up to 500, preferably up to 400, preferably up to 300, preferably up to 200 and in particular up to 150 consecutive A nucleotides.
- the cleavage takes place in the method according to the invention in all aspects, preferably with the aid of a restriction site, which is preferably a restriction site for a restriction endonuclease of the type IIS.
- the IIS restriction endonuclease recognition sequence is located downstream and 5-26 base pairs, preferably 24-26 base pairs, away from the 3 'end of the nucleic acid sequence which, when transcribed for a nucleotide sequence of at least 20 consecutive A- Nucleotides encoded.
- the invention also relates to RNA obtainable by the methods according to the invention for in vitro transcription of a selected RNA molecule.
- the RNA preparation obtainable by the methods of the invention for in vitro transcription of a selected RNA molecule from a nucleic acid molecule of the invention as a template is homogeneous or substantially homogeneous with respect to the length of the poly (A) sequence of the RNA in more than 90%, preferably more than 95%, preferably more than 98% or 99% of the RNA molecules present in the preparation, the length of the poly (A) sequence differs by not more than 10, preferably not more than 5 , 4, 3, 2 or 1 A nucleotides.
- the invention can be used, for example, to increase the expression of recombinant proteins in cellular transcription and expression.
- the modifications described according to the invention and a combination thereof can be introduced into expression vectors and used to increase the transcription of recombinant nucleic acids and expression of recombinant proteins in cell-based systems.
- These include, for example, the production of recombinant antibodies, hormones, cytokines, enzymes, etc. This allows, among other things, the reduction of production costs.
- modifications described according to the invention as well as a combination thereof can be used for gene therapy applications.
- the modifications may be introduced into gene therapy vectors and thus used to increase the expression of a transgene.
- Any nucleic acid based (DN A / RNA) vector systems e.g., plasmids, adenoviruses, poxvirus vectors, influenza virus vectors, alphavirus vectors, etc.
- DN A / RNA vector systems e.g., plasmids, adenoviruses, poxvirus vectors, influenza virus vectors, alphavirus vectors, etc.
- Transfection of cells with these vectors can be performed in vitro, e.g. in lymphocytes or dendritic cells, or also in vivo by direct application.
- Coding ribonucleic acids can be used, for example, for the transient expression of genes, possible applications for RNA-based vaccines, which are transfected into cells in vitro or administered directly in vivo, a transient expression of functional recombinant proteins in vitro, e.g. to initiate differentiation processes in cells or to study functions of proteins, and transient expression of functional recombinant proteins such as erythropoietin, hormones, anticoagulants, etc., in vivo, especially as pharmaceuticals.
- RNA in particular in vitro transcribed RNA, which is modified by the modifications described according to the invention, can be used in particular for transfecting antigen-presenting cells and thus as a tool for supplying the antigen to be presented and for loading antigen-presenting cells in which the antigen to be presented corresponds to the peptide or protein expressed by the RNA or in particular is derived therefrom by intracellular processing such as cleavage, ie the antigen to be presented is, for example, a fragment of the peptide or protein expressed by the RNA.
- antigen presenting cells can be used to stimulate T cells, especially CD4 + and / or CD8 + T cells.
- Nucleic acids cultivation of cells and introduction of nucleic acids, in particular RNA, into cells, in particular electroporation and lipofection, can be used. Enzymatic reactions are carried out according to the manufacturer's instructions or in a manner known per se.
- a nucleic acid molecule or a nucleic acid sequence according to the invention relates to a nucleic acid which is preferably deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
- Nucleic acids according to the invention comprise genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules.
- a nucleic acid can be present as a single-stranded or double-stranded and linear or covalently circular closed molecule.
- mRNA means "messenger RNA” and refers to a “transcript” that is produced using DNA as a template and itself encodes a peptide or protein.
- An mRNA typically comprises a 5 'untranslated region, a protein coding region and a 3' untranslated region. mRNA has a limited half-life in
- mRNA can be produced by in vitro transcription from a DNA template.
- it may be modified by further stabilizing modifications and capping.
- nucleic acid also includes a chemical derivatization of a
- nucleic acid at a nucleotide base, at the sugar or at the phosphate, and nucleic acids containing non-naturally occurring nucleotides and nucleotide analogs refers to a nucleic acid in which, compared to the nucleic acid from which it is derived, single or multiple nucleotide substitutions, deletions and / or additions are present and which are linked to the nucleic acid of It is preferably complementary, that is, there is some degree of homology between the nucleic acids and the nucleic acids have significant direct or complementary matches in the sequence of their nucleotides
- a nucleic acid derived from a nucleic acid has a functional property of the nucleic acid according to the invention from which it is derived Such functional properties include, in particular, the ability to confer stability and / or translation efficiency upon functional association with a nucleic acid transcribable in RNA (transcribable nu
- a nucleic acid is "operably linked" when placed in a functional relationship with another nucleic acid sequence.
- a promoter is operably linked to a coding sequence if it affects the transcription of the coding sequence.
- Functionally linked nucleic acids are typically adjacent to each other, optionally separated by additional nucleic acid sequences, and in certain embodiments are transcribed into a single RNA (common transcript) molecule by RNA polymerase.
- isolated nucleic acid means that the nucleic acid (i) was amplified in vitro, for example by polymerase chain reaction (PCR), (ii) was produced recombinantly by cloning, (iii) was purified, for example by cleavage and gel electrophoretic separation, or (iv) was synthesized, for example by chemical synthesis.
- An isolated nucleic acid is a nucleic acid available for manipulation by recombinant DNA techniques.
- a nucleic acid is then "complementary" to another nucleic acid if the two sequences hybridize to one another and can form a stable duplex, the hybridization preferably taking place under conditions involving specific hybridization between polynucleotides (stringent conditions). Stringent conditions are described, for example, in Molecular Cloning: A Laboratory Manual, J.
- Complementary nucleic acids according to the invention have at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98% or at least 99% identity of the nucleotides.
- % identity is intended to indicate a percentage of nucleotides identical between two sequences to be compared in an optimal alignment, this percentage being purely statistical, the differences between the two sequences being random and distributed over the entire sequence length, and the sequence to be compared may include additions or deletions compared to the reference sequence to achieve optimal alignment between two sequences.
- Sequence comparisons between two sequences are generally performed by comparing these sequences for optimal alignment with respect to a segment or "comparison window" to identify local regions of sequence match.
- the optimal alignment for a comparison can be done manually or using the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, using the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol.
- the percent identity is obtained by determining the number of identical positions in which the sequences to be compared match, dividing this number by the positions compared, and multiplying this result by 100.
- BLAST 2 sequences available from the website http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi can be used.
- nucleic acid refers to the end on which a free hydroxy group is located
- 3' end is always on the right
- 5 'end of one Nucleic acid according to the invention relates to that end to which a free phosphate group is located.
- the 5 'end is always on the left.
- a nucleic acid according to the invention is functionally in association with expression control sequences which may be homologous or heterologous relative to the nucleic acid.
- a transcribable nucleic acid in particular a nucleic acid coding for a peptide or protein, and an expression control sequence are then "functionally" linked to each other if they are covalently linked to one another in such a way that the transcription or expression of the transcribable and in particular coding nucleic acid under the
- nucleic acid is to be translated into a functional peptide or protein
- induction of the expression control sequence leads to transcription of the coding sequence without resulting in frame shift in the coding sequence or inability of the coding sequence coding sequence comes to be translated into the desired peptide or protein.
- expression control sequence comprises promoters, ribosome binding sequences and other control elements which control the transcription of a gene or the translation of the derived RNA
- the expression control sequences are regulatable
- the exact structure of expression control sequences may vary depending on the species or cell type, but includes generally 5'-untranscribed and 5'- and 3'-untranslated sequences involved in the initiation of transcription, such as TATA box, capping sequence, CAAT sequence and the like
- Non-transcribed expression control sequences include a promoter region that includes a promoter sequence for transcriptional control of the functionally linked gene.
- Expression control sequences may also include enhancer sequences or upstream activator sequences.
- nucleic acids shown here in particular transcribable and coding nucleic acids, can be used with any expression control sequences, in particular
- Promoters which may be homologous or heterologous to the nucleic acids, wherein the term “homologous” denotes that a nucleic acid is also naturally functionally linked to the expression control sequence and the term “heterologous” denotes that a nucleic acid does not naturally interact with the expression control sequence is functionally connected.
- promoter refers to a DNA sequence located upstream (5 ') to the coding sequence of a gene and directing the expression of the coding sequence by providing a recognition and binding site for RNA polymerase.
- the promoter region can provide additional recognition or binding sites for further
- a promoter may direct transcription of a prokaryotic or eukaryotic gene.
- a promoter may be "inducible” and initiate transcription in response to an inducer, or it may be “constitutive” if transcription is not controlled by an inducer.
- An inducible promoter is not expressed or expressed only to a very small extent if an inducer is missing. In the presence of the inducer, the gene is "turned on” or the level of transcription increased. This is conventionally mediated by the binding of a specific transcription factor.
- Promotors which are preferred according to the invention are, for example, promoters for SP6, T3 or T7 polymerase.
- RNA Ribonucleic acid
- RNA and protein Ribonucleic acids
- the expression can be transient or stable.
- RNA the term “expression” or “translation” relates in particular to the production of peptides or proteins.
- nucleic acids that can be transcribed into a common transcript means that the nucleic acids are functionally linked to one another such that, optionally after linearization such as cleavage by restriction enzyme of the nucleic acid molecule comprising the nucleic acids, in particular a circularly closed nucleic acid molecule, transcription Control of a promoter in an RNA molecule results, which comprises the transcripts of the nucleic acids in covalent bond to each other, optionally separated by intervening sequences.
- transcription comprises “in vitro transcription”, wherein the term “in vitro transcription” refers to a method in which RNA, in particular mRNA, is synthesized cell-free, ie preferably using appropriately prepared cell extracts, in vitro
- cloning vectors are used, which are generally referred to as transcription vectors and are encompassed by the term “vector” according to the invention.
- nucleic acid sequence transcribed from a nucleic acid sequence refers to RNA, optionally as part of a total RNA molecule, which is a transcription product of the first nucleic acid sequence.
- nucleic acid sequence which is effective, the translation efficiency and / or the
- the first nucleic acid is capable of modifying, in a common transcript with the second nucleic acid, the translational efficiency and / or the stability of the second nucleic acid in such a way that it differs from the translation efficiency and / or the nucleic acid Stability of the second Nucleic acid without the first nucleic acid is increased.
- translation efficiency in this context refers to the amount of translation product provided by an RNA molecule in a given period of time
- stability refers to the half-life of an RNA molecule.
- the 3 'untranslated region refers to a region that is transcribed at the 3' end of a gene downstream of the termination codon of a protein-coding region, but is not translated into an amino acid sequence.
- a first polynucleotide region is considered downstream to a second polynucleotide region when the 5 'end of the first polynucleotide region is the nearest to the 3' end of the second polynucleotide region of the first polynucleotide region.
- the 3 'untranslated region typically extends from the translation codon for a translation product to the poly (A) sequence conventionally added after the transcription process.
- the 3 'untranslated regions of mammalian mRNA typically have a region of homology known as the AAUAAA hexanucleotide sequence. This sequence is believed to be the poly (A) add signal. Often it is 10 to 30 bases before the poly (A) attachment site.
- 3 'untranslated regions may contain one or more inverted repeats that can fold into stem-loop structures that act as a barrier to exoribonucleases or interact with proteins known to increase RNA stability (eg RNA-binding proteins).
- 5'- and / or 3'-untranslated regions according to the invention may be operably linked to a transcribable and especially coding nucleic acid, so that these regions in such a relationship with the nucleic acid that the stability and / or translation efficiency of the transcribable Nucleic acid transcribed
- RNA increased.
- the 3 'untranslated regions of immunoglobulin mRNAs are relatively short (less than about 300 nucleotides), while the 3' untranslated regions of other genes are relative are long.
- the 3'-untranslated region of tPA is about 800 nucleotides long
- that of factor VIII is about 1800 nucleotides long
- that of erythropoietin is about 560 nucleotides long.
- a 3'-untranslated region or a nucleic acid sequence derived therefrom enhances the stability and / or translation efficiency of RNA by incorporating the 3'-untranslated region or the nucleic acid sequence derived therefrom into the 3'-non-translated region.
- translated region of a gene is measured and it is measured whether this incorporation increases the amount of synthesized protein.
- a nucleic acid comprises 2 or more 3'-untranslated regions, preferably sequentially with or without an intermediate linker, preferably in a "head-to-tail relationship" (ie the 3 'untranslated regions have the same orientation, preferably the orientation naturally occurring in a nucleic acid).
- the term "gene” refers to a particular nucleic acid sequence which is responsible for the production of one or more cellular products and / or for the achievement of one or more intercellular or intracellular functions, in particular the term refers to a DNA segment which comprises a nucleic acid, which codes for a specific protein or a functional or structural RNA molecule.
- polyadenyl cassette or "poly (A) sequence” refer to a sequence of adenyl residues, typically at the 3 'end of an RNA molecule. According to the invention, such a sequence is added by a DNA template based on repeating thymidyl residues in the strand complementary to the coding strand upon transcription of RNA, whereas normally it is not encoded in the DNA but by a template-independent strand RNA polymerase is attached to the free 3 'end of the RNA after transcription in the nucleus.
- a nucleic acid molecule according to the invention is a vector.
- vector is used in its most general sense and encompasses any intermediate vehicle for a nucleic acid, e.g. enable the nucleic acid to be introduced into prokaryotic and / or eukaryotic host cells and optionally integrated into a genome. Such vectors are preferably replicated and / or expressed in the cell. Vectors include plasmids, phagemids or viral genomes.
- plasmid refers generally to a construct of extrachromosomal genetic material, usually a circular DNA duplex, that can replicate independently of chromosomal DNA.
- the term “host cell” refers to any cell that is transformable or transfectable with an exogenous nucleic acid.
- the term "host cell” according to the invention comprises prokaryotic (for example E. coli) or eukaryotic cells (for example yeast cells and insect cells). Particularly preferred are mammalian cells such as human, mouse, hamster, pig, goat, primate cells.
- the cells can be derived from a variety of tissue types and include primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells and embryonic
- the host cell is an antigen-presenting cell, in particular a dendritic cell, a monocyte or a macrophage.
- a nucleic acid may be present in the host cell in single or multiple copies and in one embodiment is expressed in the host cell.
- a peptide or protein encoded by a nucleic acid may be a peptide or protein that is localized or secreted in the cytoplasm, in the nucleus, in the membrane, in organelles. They include structural proteins, regulatory proteins, hormones, neurotransmitters, growth-regulating factors, differentiation factors, gene expression regulating factors, DNA-associated proteins, enzymes, serum proteins,
- peptide refers to substances which are two or more, preferably 3 or more, preferably 4 or more, preferably 6 or more, preferably 8 or more, preferably 10 or more, preferably 13 or more, preferably 16 or more, preferably 20 or more and up to preferably 50, preferably 100 or preferably 150 consecutive amino acids joined together by peptide bonds.
- protein refers to large peptides, preferably peptides having at least 151 amino acids, but the terms “peptide” and “protein” are generally used herein as synonyms.
- peptide and protein include according to the invention substances which contain not only amino acid constituents but also non-amino acid constituents such as sugars and phosphate structures and also comprise substances which contain bonds such as ester, thioether or disulfide bonds.
- nucleic acids in particular RNA
- administration of nucleic acids is by ex vivo methods, i. by removing cells from a patient, genetically altering the cells, and reintroducing the altered cells into the patient. Transfection and transduction methods are known in the art. Also provided according to the invention is administration of nucleic acids in vivo.
- transfection relates to the introduction of one or more
- Nucleic acids in an organism or in a host cell can be used to introduce according to the invention nucleic acids in cells in vitro or in vivo. Such methods include transfection of nucleic acid CaPO 4 precipitates, transfection of nucleic acids associated with DEAE, transfection or infection with viruses carrying the nucleic acids of interest
- a carrier used to deliver a nucleic acid to a cell may have a bound targeting molecule.
- a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be incorporated into or bound to the nucleic acid carrier.
- proteins that bind to a surface membrane protein can associate with endocytosis is incorporated into the liposome formulation to allow for targeting and / or uptake.
- proteins include capsid proteins or fragments thereof that are specific for a particular cell type, antibodies against proteins that are being intercalated, proteins that target an intracellular site, and the like.
- Reporter refers to a molecule, typically a peptide or protein, that is encoded by a reporter gene and measured in a reporter test. Conventional systems generally use an enzymatic reporter and measure the activity of the reporter.
- multiple cloning site refers to a nucleic acid region containing restriction enzyme sites, any of which may be used for cleavage of, for example, a vector and insertion of a nucleic acid.
- two elements such as nucleotides or amino acids, are consecutive if they are immediately adjacent to one another without an interruption.
- a sequence of x consecutive nucleotides N refers to the sequence (N) x .
- Restriction endonuclease or “restriction enzyme” refers to a class of enzymes that are present in both strands of a DNA molecule within specific base sequences
- split phosphodiester bonds They recognize specific binding sites on a double-stranded DNA molecule, which are called recognition sequences.
- the sites where the phosphodiester bonds in the DNA are cleaved by the enzymes are called cleavage sites.
- the interface is located at a defined distance from the DNA binding site. The term "restriction
- Endonuclease includes according to the invention, for example, the enzymes SapI, Ecil, Bpil, Aarl, AIoI, Bael, BbvCI, Ppil and PsrI, BsrDl, BtsI, Earl, Bmrl, Bsal, BsmBI, Faul, Bbsl, BciVI, BfuAI, BspMI, BseRI, Ecil , BtgZI, BpuEI, Bsgl, Mmel, CspCI, Bael, BsaMI, Mval269I, PctI, Bse3DI, BseMI, BstIII, EamI 1041, Ksp632I, Bfil, Bso31I, BspTI, Eco31I, Esp3I, BfuI, Acc36I, Aarl, Eco57I, Eco57MI, Gsul, AloI, Hin4I, Ppil, and PsrI
- Half-life refers to the amount of time needed to eliminate half of the activity, amount or number of molecules.
- FIG. 1 Basis vectors used according to the invention for the further cloning
- the vectors permit transcription of RNA under the control of a 5 'RNA polymerase promoter and contain a polyadenyl cassette.
- Fig. 2 Linearization of restriction enzyme type II (e.g., Spei) vectors as compared to IIS restriction enzymes (e.g., SapI)
- restriction enzyme type II e.g., Spei
- IIS restriction enzymes e.g., SapI
- FIG. 3 Vectors which have been prepared according to the invention as a template for in vitro transcription
- RNA modifications according to the invention were prepared, which subsequently served as template for the in vitro transcription, a. Vectors with hidden versus uncovered poly (A) sequence; b. Vectors of different length poly (A) sequence; c. Vectors with 3 'untranslated region from human beta globin; d. SIINFEKL and pp65 vectors; Cap - 5'-capping; eGFP - GFP reporter gene; 3' ⁇ g - 3 'untranslated region of ⁇ -globin; A (x) -x denotes the numbers of A nucleotides in the poly (A) sequence.
- Fig. 4 Determination of the maturation status of immature versus mature dendritic cells over the indicated surface markers
- RNA modifications according to the invention were tested in human dendritic cells (DC), wherein an immunogenic stimulus causes a maturation process of the DCs.
- the DCs were stained with anti-CD80, anti-CD83, anti-CD86 and anti-HLA-DR antibodies which recognize specific DC maturation markers and analyzed by flow cytometry.
- Fig. 5 Influence of free versus hidden poly (A) sequence on translation efficiency and transcript stability a. Influence of free versus covert poly (A) sequence on the translation efficiency of eGFP RNA in K562 and dendritic cells by the determination of the mean fluorescence intensity [MFI] in the FACS caliber; b.
- RNA with open ended poly (A) sequence is translated more efficiently and over a longer period of time than RNA with covertly ending poly (A) sequence.
- the translational efficiency in an uncovered poly (A) sequence in DCs is increased by 1.5 times.
- An open ended poly (A) sequence also results in a higher stability of the RNA.
- Fig. 6 Influence of the length of the poly (A) sequence on the translation efficiency and transcript stability a. Influence of the length of the poly (A) sequence on the translation efficiency of eGFP RNA in K562 and dendritic cells; b. Influence of the length of the poly (A) sequence on the translation efficiency of d2eGFP RNA in K562 and dendritic cells; c. Influence of the length of the poly (A) sequence on the transcript stability of eGFP RNA in K562 cells 48h after electroporation. An extension of the poly (A) sequence to up to 120 A
- Nucleotides increase the stability and translation of the transcript. Any extension beyond this has no positive effect. By extending the poly (A) sequence from 51 to 120 A nucleotides, a 1.5 to 2-fold increase in translation efficiency is achieved. This effect is also reflected in the stability of the RNA.
- FIG. 7 Influence of a 3'-untranslated region of human beta-globin (BgUTR) on translation efficiency in immature and mature DCs. Insertion of a 3 'untranslated region of human beta-globin results in increased expression of the RNA. transcript. A double 3 'untranslated region of human beta-globin results in an improvement in expression level after 24 h that clearly exceeds the summation effect of two single 3' untranslated region of human beta-globin.
- FIG. 8 Effect of the modifications according to the invention in combination on the translation efficiency in immature and mature DCs
- the translation efficiency of eGFP in immature and mature DCs can be increased more than fivefold.
- FIG. 9 Effect of the modifications according to the invention in combination on the presentation of peptides by MHC molecules on EL4 cells
- modified RNA constructs according to the invention leads to increased presentation of peptide-MHC due to the increased translation efficiency.
- eGFP was replaced in the described IVT vectors by the OVA257-264 epitope (SIINFEKL) and used as target cells for transfection EL4 cells (murine, T-cell lymphoma).
- FIG. 10 Increase of antigen-specific peptide / MHC complexes by using inventively stabilized IVT-RNA constructs
- FIG. 11 Effect of inventively stabilized IVT-RNA constructs on the T
- lxlO 5 -TCR transgenic CD8 + OT-I cells were adoptively transferred to C57B1 / J6 mice.
- CD8 + and CD4 + lymphocytes from HCMV seropositive healthy donors were co-cultured with autologous DCs co-cultured with Sec-pp65-A67-ACUAG RNA, Sec-pp65-2BgUTR-A 120 RNA, or control RNA (data not shown) or pulsed with pp65 peptide pool (1.75 ⁇ g / ml) as a positive control.
- each effector cell population (4x10 4 AVeIl) in an IFN- ⁇ ELISpot was challenged with autologous DC (3xlO 4 ⁇ Vell) loaded with either pp65 peptide pool or an irrelevant peptide pool (1.75 ⁇ g / ml). , tested.
- the plot shows the average number of spots of triple measurements ⁇ SEM.
- RNA modifications according to the invention were prepared which served as templates for in vitro transcription (FIG. 3).
- the reporter genes for eGFP or d2eGFP two molecules with different half-life (HWZ), introduced, whereby it is possible to analyze the influence of the RNA modifications of the invention.
- the fluorescence decays with an average HWZ of 17.3 h in eGFP and 2 h in d2eGFP.
- HWZ half-life
- Example 2 Transfection of cells with the in vitro modified transcribed RNA according to the invention and effect on the translation and stability of the RNA
- eGFP RNA or d2eGFP RNA was used to transfect K562 cells (human, leukemia) by electroporation. The transfection efficiency was> 90% in K562 cells.
- RNA transfected DCs are to be considered for vaccination.
- Immature DCs are localized in the skin and peripheral organs. They are here in an immature state characterized by well-studied surface markers and functionally characterized by a strong endocytic activity.
- an immunogenic stimulus e.g. an infection with pathogens
- a maturing process of the DCs is triggered.
- their migration into the regional lymph nodes is initiated, where they are the most potent inducers of T-cell and
- B cell immune responses are.
- the mature state of the DCs is also characterized by the expression of detailed surface markers and cytokines as well as a characteristic morphology of the DCs.
- the expression level and duration were determined by means of the FACS caliber on the determination of the fluorescence intensity of the eGFP.
- the determination of the amount of RNA in the cells was carried out by means of a quantitative RT-PCR.
- RNA with open-ended poly (A) sequence is translated more efficiently and over a longer period of time than RNA with covertly ending poly (A) sequence (Fig 5a).
- RNA with covertly ending poly (A) sequence For the same length of the poly (A) sequence, translational efficiency with an unobstructed poly (A) sequence in immature DCs is increased 1.5-fold.
- the modification also leads to a higher stability of the RNA ( Figure 5b). 48 hours after electroporation, in immature DCs transfected with RNA with an unseen poly (A) sequence, 4 to 5 times the amount of RNA is detectable.
- RNA with lengths of the poly (A) sequence of 16bp, 42bp, 51bp, 67bp, 120bp, 200bp, 300bp, and 600bp revealed that extension of the poly (A) sequence to up to 120 A nucleotides An increase in transcript stability and translation leads and that a more extensive extension has no positive effect. This effect is evident in both K562 cells and immature DCs (iDC) ( Figures 6a and 6b).
- Example 3 Presentation of a peptide expressed by in vitro transcribed RNA with increased stability and translational efficiency by MHC molecules
- RNA constructs modified according to the invention leads to an increased peptide MHC presentation on the cell surface.
- the nucleic acid sequence coding for the eGFP in the described IVT vectors was replaced by a nucleic acid sequence coding for the OVA257-264 epitope (SIINFEKL), and the constructs were compared with one another.
- Target cells for transfection were EL4 cells (murine, T-cell lymphoma).
- SIINFEKL peptide was incorporated into the vector that reflected all optimizations (pSTI-Sec-SIINFEKL-2BgUTR-A120-SapI) and into a vector Standard features (pSTI-Sec-SIINFEKL-A67-Spel) cloned.
- IVT RNA derived from both vectors was electroporated into EL4 cells and BMDC. Significantly higher numbers of OVA peptide / K b complexes on the cell surface were observed, which were maintained over a longer time course after electroporation of the RNA modified according to the invention, Sec-SIINFEKL-2 BgUTR-A120 (FIG. 10).
- Example 4 Effect of transfecting cells with in vitro transcribed RNA encoding a peptide to be displayed on the expansion of antigen-specific T cells
- OT-I TCR T cell receptor
- mice were adoptively transferred with OT-I CD8 + T cells.
- splenocytes from TCR tg OT-I mice were prepared and introduced into the tail vein of C57BL / J6 recipient mice. The cell count was adjusted to 1x10 5 TCR tg CD8 + T cells.
- 1x10 BMDC from C57BL / J6 mice electroporated with 50 pmol SIINFEKL-encoding RNA construct variants and matured for 16 hours by poly (I: C) were ip administered to mice.
- OT-I CD8 + T cells were measured in peripheral blood using tetramer technology.
- retro-orbital blood samples were taken and incubated with anti-CD8 (Caltag Laboratories, Burlingame,
- SIINFEKL tetramer H-2Kb / SIINFEKL 257-264; Beckman Coulter, Fullerton, USA.
- CD4 + and CD8 + T cells purified from HCMV seropositive healthy donors by positive magnetic cell sorting using antibody-coated microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) were co-cultured with 2x10 5 autologous DCs that were electroporated with the corresponding IVT-RN A variants encoding pp65.
- Expansion of T cells measured at day 7 in an IFN- ⁇ ELISpot using autologous DC pulsed with a pool of overlapping peptides covering the entire pp65 protein sequence or a control protein showed superiority of Sec-pp65-2BgUTR-A 120, with the most pronounced effects on CD4 + T cell expansion (Figure I IB).
- a carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2, 59-65.
- Bovine yeast virus 1 immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67, 5664-5667.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06805937T PL1934345T3 (pl) | 2005-09-28 | 2006-09-28 | Modyfikacje RNA prowadzące do zwiększonej stabilności transkryptu i skuteczności translacji |
US11/992,638 US9476055B2 (en) | 2005-09-28 | 2006-09-28 | Modification of RNA, producing an increased transcript stability and translation efficiency |
SI200631340T SI1934345T1 (sl) | 2005-09-28 | 2006-09-28 | Modifikacije RNA ki vodijo do povečane transkripcijske stabilnosti in translacijske učinkovitosti |
DK06805937.7T DK1934345T3 (da) | 2005-09-28 | 2006-09-28 | Modifikationer af rna, der fører til en forøget transkriptstabilitet og translationseffektivitet |
AU2006296702A AU2006296702B2 (en) | 2005-09-28 | 2006-09-28 | Modification of RNA, producing an increased transcript stability and translation efficiency |
RS20120238A RS52353B (en) | 2005-09-28 | 2006-09-28 | RNA MODIFICATIONS INCREASING TRANSCRIPTION STABILITY AND TRANSLATION EFFICIENCY |
ES06805937T ES2384113T3 (es) | 2005-09-28 | 2006-09-28 | Modificación del ARN, que produce unas estabilidad de transcripción y eficiencia de traducción aumentadas |
AT06805937T ATE550427T1 (de) | 2005-09-28 | 2006-09-28 | Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen |
IN2116CHN2014 IN2014CN02116A (de) | 2005-09-28 | 2006-09-28 | |
JP2008532678A JP5435949B2 (ja) | 2005-09-28 | 2006-09-28 | 転写産物の安定性と転写効率の向上をもたらすrnaの修飾 |
CA2621444A CA2621444C (en) | 2005-09-28 | 2006-09-28 | Modification of rna, producing an increased transcript stability and translation efficiency |
EP06805937A EP1934345B9 (de) | 2005-09-28 | 2006-09-28 | Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen |
HRP20120480TT HRP20120480T1 (hr) | 2005-09-28 | 2012-06-08 | Modifikacije rnk koje povećavaju stabilnost trankripcije i efikasnost translacije |
US15/217,555 US10106800B2 (en) | 2005-09-28 | 2016-07-22 | Modification of RNA, producing an increased transcript stability and translation efficiency |
US16/143,520 US20190062762A1 (en) | 2005-09-28 | 2018-09-27 | Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency |
US18/049,593 US20230193296A1 (en) | 2005-09-28 | 2022-10-25 | Modification of rna, producing an increased transcript stability and translation efficiency |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005046490.4 | 2005-09-28 | ||
DE102005046490A DE102005046490A1 (de) | 2005-09-28 | 2005-09-28 | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/992,638 A-371-Of-International US9476055B2 (en) | 2005-09-28 | 2006-09-28 | Modification of RNA, producing an increased transcript stability and translation efficiency |
US15/217,555 Division US10106800B2 (en) | 2005-09-28 | 2016-07-22 | Modification of RNA, producing an increased transcript stability and translation efficiency |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007036366A2 true WO2007036366A2 (de) | 2007-04-05 |
WO2007036366A3 WO2007036366A3 (de) | 2007-06-21 |
WO2007036366A8 WO2007036366A8 (de) | 2012-05-31 |
Family
ID=37685276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/009448 WO2007036366A2 (de) | 2005-09-28 | 2006-09-28 | Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen |
Country Status (18)
Country | Link |
---|---|
US (4) | US9476055B2 (de) |
EP (2) | EP2357230B1 (de) |
JP (3) | JP5435949B2 (de) |
AT (1) | ATE550427T1 (de) |
AU (1) | AU2006296702B2 (de) |
CA (2) | CA2621444C (de) |
CY (2) | CY1113526T1 (de) |
DE (1) | DE102005046490A1 (de) |
DK (2) | DK2357230T3 (de) |
ES (2) | ES2467678T3 (de) |
HK (1) | HK1155477A1 (de) |
HR (2) | HRP20120480T1 (de) |
IN (1) | IN2014CN02116A (de) |
PL (2) | PL2357230T3 (de) |
PT (2) | PT1934345E (de) |
RS (2) | RS52353B (de) |
SI (2) | SI1934345T1 (de) |
WO (1) | WO2007036366A2 (de) |
Cited By (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
EP2281579A1 (de) | 2009-08-05 | 2011-02-09 | BioNTech AG | Impfstoffzusammensetzung mit 5'-Cap-modifizierter RNA |
WO2012019780A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
JP2012523231A (ja) * | 2009-04-10 | 2012-10-04 | オブシェストヴォ エス オグラニヒェンノイ オトヴェツトヴェンノストユ “ラボラトリア クレトフニクフ テクノロギイ” | 多能性幹細胞の製造方法 |
WO2013120627A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120626A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120628A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120629A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013151668A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of secreted proteins |
WO2013151666A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015095351A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2016091391A1 (en) * | 2014-12-12 | 2016-06-16 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
EP3178488A1 (de) | 2012-02-15 | 2017-06-14 | CureVac AG | Nucleinsäure mit oder zur codierung einer histon-haarnadelstruktur und poly(a)-sequenz oder ein polyadenylationssignal zur erhöhung der expression eines codierten tumorantigens |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
WO2017182524A1 (en) | 2016-04-22 | 2017-10-26 | Biontech Rna Pharmaceuticals Gmbh | Methods for providing single-stranded rna |
WO2017182634A1 (en) | 2016-04-22 | 2017-10-26 | Curevac Ag | Rna encoding a tumor antigen |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
WO2017201350A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
EP3348645A1 (de) | 2012-02-15 | 2018-07-18 | CureVac AG | Nukleinsäure mit einer histon-stammschleife und einer poly(a)-sequenz oder zu deren codierung oder polyadenylierungssignal zur erhöhung der expression eines codierten pathogenen antigens |
US10093736B2 (en) | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
EP3404103A1 (de) | 2012-02-15 | 2018-11-21 | CureVac AG | Nucleinsäure, enthaltend eine oder codierend für eine histon-stammschleife und eine poly(a)-sequenz oder ein polyadenylierungssignal zur erhöhung der expression eines codierten allergen-antigens oder eines autoimmunen selbstantigens |
US10155031B2 (en) | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
US10414824B2 (en) | 2002-11-22 | 2019-09-17 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
WO2019175356A1 (en) | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
WO2020127532A2 (en) | 2018-12-19 | 2020-06-25 | Versameb Ag | Rna encoding a protein |
US10717982B2 (en) | 2014-07-11 | 2020-07-21 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(A) sequence encoding DNA sequences |
US10738355B2 (en) | 2011-05-24 | 2020-08-11 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
EP3334828B1 (de) | 2015-08-10 | 2020-10-28 | CureVac Real Estate GmbH | Verfahren zur erhöhung der replikation eines zirkulären dna-moleküls |
EP3766903A2 (de) | 2012-11-13 | 2021-01-20 | BioNTech SE | Bispezifischer antikörper anti claudin xcd3 zur behandlung von krebserkrankungen mit claudin-expression |
WO2021008708A1 (en) | 2019-07-18 | 2021-01-21 | Biontech Rna Pharmaceuticals Gmbh | Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles |
WO2021160346A1 (en) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
WO2022016125A1 (en) | 2020-07-17 | 2022-01-20 | Genentech, Inc. | Attention-based neural network to predict peptide binding, presentation, and immunogenicity |
US20220125723A1 (en) | 2010-07-06 | 2022-04-28 | Glaxosmithkline Biologicals Sa | Lipid formulations with viral immunogens |
WO2022101471A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Pharmaceutical compositions comprising lipid nanoparticles and mrna, and methods for preparing and storing the same |
WO2022101470A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
US11400169B2 (en) | 2014-10-09 | 2022-08-02 | Seattle Children's Hospital | Long poly(A) plasmids and methods for introduction of long poly(A) sequences into the plasmid |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022218891A2 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
WO2022218503A1 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
WO2022228827A1 (en) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
WO2022235847A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Technologies for early detection of variants of interest |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
WO2023006920A1 (en) | 2021-07-29 | 2023-02-02 | BioNTech SE | Compositions and methods for treatment of melanoma |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
US11596645B2 (en) | 2010-07-06 | 2023-03-07 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023036960A1 (en) | 2021-09-10 | 2023-03-16 | BioNTech SE | Lipid-based rna formulations suitable for therapy |
WO2023052531A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
EP4169578A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
EP4169534A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
EP4169579A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfid-oligosaccharid-verbindungen und -komplexe |
EP4169580A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
US11639370B2 (en) | 2010-10-11 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Antigen delivery platforms |
WO2023073190A1 (en) | 2021-10-28 | 2023-05-04 | BioNTech SE | Rna constructs and uses thereof |
WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
US11655475B2 (en) | 2010-07-06 | 2023-05-23 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
EP4186528A1 (de) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
WO2023126404A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023148276A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery to cells |
WO2023148277A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery of nucleic acids to cells |
WO2023166099A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | RNA LIPID NANOPARTICLES (LNPs) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE POLYMER |
US11759422B2 (en) | 2010-08-31 | 2023-09-19 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding RNA |
WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
EP4286004A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfid-oligosaccharid-verbindungen und -komplexe |
EP4286003A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
EP4285932A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
EP4286394A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
EP4285933A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024028325A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions |
US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
WO2024064886A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Using n-terminal degrons to enhance rna t cell vaccine immunogenicity |
WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2971010B1 (de) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3052106A4 (de) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynukleotide zur codierung immunmodulierender polypeptide |
EP3052521A1 (de) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynukleotide zur codierung von low-density-lipoprotein-rezeptor |
HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
EP3359670B2 (de) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Verfahren zur therapeutischen verabreichung messenger-ribonukleinsäure-arzneimitteln |
SI3362461T1 (sl) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Analogi kape MRNA z modificirano fosfatno povezavo |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
EP3362460A1 (de) * | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna-kappenanaloga und verfahren zum mrna-kappen |
SI3394093T1 (sl) | 2015-12-23 | 2022-05-31 | Modernatx, Inc. | Metode uporabe liganda OX40, ki kodira polinukleotid |
US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
MA45041A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
WO2017201346A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
MA45036A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 |
JP7114485B2 (ja) | 2016-05-18 | 2022-08-08 | モデルナティエックス インコーポレイテッド | ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド |
WO2017201332A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
AU2017266929B2 (en) | 2016-05-18 | 2023-05-11 | Modernatx, Inc. | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof |
MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
CA3030701A1 (en) | 2016-07-11 | 2018-01-18 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
WO2018081788A1 (en) | 2016-10-31 | 2018-05-03 | Cornell University | Methods of enhancing translation ability and stability of rna molecules, treatments, and kits |
AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
US20200268666A1 (en) | 2017-06-14 | 2020-08-27 | Modernatx, Inc. | Polynucleotides encoding coagulation factor viii |
US20200254086A1 (en) | 2017-08-18 | 2020-08-13 | Moderna TX, Inc. | Efficacious mrna vaccines |
WO2019104152A1 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
CA3079543A1 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
CA3084824A1 (en) | 2017-12-15 | 2019-06-20 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
EP3735270A1 (de) | 2018-01-05 | 2020-11-11 | Modernatx, Inc. | Für anti-chikungunya-virus-antikörper codierende polynukleotide |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
EP3773745A1 (de) | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger-rna mit funktionalen rna-elementen |
WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
MA53545A (fr) | 2018-09-02 | 2021-07-14 | Modernatx Inc | Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne |
WO2020056155A2 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
MA53609A (fr) | 2018-09-13 | 2021-07-21 | Modernatx Inc | Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose |
US20230081530A1 (en) | 2018-09-14 | 2023-03-16 | Modernatx, Inc. | Methods and compositions for treating cancer using mrna therapeutics |
CA3112398A1 (en) | 2018-09-14 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
EP3856233A1 (de) | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Arginase-1-codierende polynukleotide zur behandlung von arginasemangel |
EP3911678A1 (de) | 2019-01-14 | 2021-11-24 | Genentech, Inc. | Verfahren zur behandlung von krebs mit einem pd-1-achsen-bindenden antagonisten und einem rna-impfstoff |
JP2022523222A (ja) | 2019-03-01 | 2022-04-21 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | ポリリボヌクレオチドの送達のための組成物、方法、及びキット |
CA3128644A1 (en) | 2019-03-01 | 2020-09-10 | Avak Kahvejian | Polyribonucleotides and cosmetic uses thereof |
US20230086537A1 (en) | 2019-05-07 | 2023-03-23 | Modernatx, Inc. | Differentially expressed immune cell micrornas for regulation of protein expression |
CA3139321A1 (en) | 2019-05-07 | 2020-11-12 | Modernatx, Inc. | Polynucleotides for disrupting immune cell activity and methods of use thereof |
US20220226438A1 (en) | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Compositions for skin and wounds and methods of use thereof |
TW202248419A (zh) * | 2019-05-08 | 2022-12-16 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
MA56539A (fr) | 2019-06-24 | 2022-04-27 | Modernatx Inc | Arn messager résistant à l'endonucléase et utilisations correspondantes |
US20220387628A1 (en) | 2019-06-24 | 2022-12-08 | Modernatx, Inc. | Messenger rna comprising functional rna elements and uses thereof |
US20240123034A1 (en) | 2019-10-15 | 2024-04-18 | Modernatx, Inc. | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
MX2022009280A (es) | 2020-01-28 | 2022-08-16 | Modernatx Inc | Vacunas de arn contra el coronavirus. |
CN115361954A (zh) | 2020-01-29 | 2022-11-18 | 旗舰创业创新第六有限责任公司 | 用于翻译的组合物及其使用方法 |
TW202142257A (zh) | 2020-01-31 | 2021-11-16 | 美商建南德克公司 | 用pd-1軸結合拮抗劑及rna疫苗誘導新抗原決定基特異性t細胞之方法 |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
MX2022009707A (es) | 2020-02-07 | 2022-09-07 | Modernatx Inc | Vacunas de dominio de arnm contra el sars-cov-2. |
WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
CA3182920A1 (en) | 2020-05-14 | 2021-11-18 | Modernatx, Inc. | Lnp compositions comprising an mrna therapeutic and an effector molecule |
WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
WO2021247535A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
CA3184474A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
US20230242908A1 (en) | 2020-06-23 | 2023-08-03 | Modernatx, Inc. | Lnp compositions comprising mrna therapeutics with extended half-life |
CN111893128A (zh) * | 2020-06-24 | 2020-11-06 | 苏州市泽悦生物技术有限公司 | 利用原核转录系统制备重组真核mRNA的方法及其应用 |
IL300997A (en) | 2020-09-08 | 2023-04-01 | Genentech Inc | Systems and methods for the production of pharmaceutical preparations using peristaltic pumps and restraints |
US20230355743A1 (en) | 2020-09-25 | 2023-11-09 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
WO2022090752A1 (en) | 2020-10-26 | 2022-05-05 | Pécsi Tudományegyetem | Vaccine platform |
AU2021377895A1 (en) | 2020-11-13 | 2023-06-15 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
WO2022106860A1 (en) | 2020-11-20 | 2022-05-27 | Pécsi Tudományegyetem | Recombinant peptides for use in therapy |
KR20230164648A (ko) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | SARS-CoV-2 변이체에 대한 RNA 백신 |
WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
CA3208303A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
JP2024503698A (ja) | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | 変異型株ベースのコロナウイルスワクチン |
JP2024506908A (ja) | 2021-02-12 | 2024-02-15 | モデルナティエックス インコーポレイテッド | インビボ療法のためのペイロードを含むlnp組成物 |
WO2022197624A1 (en) | 2021-03-15 | 2022-09-22 | Modernatx, Inc. | Therapeutic use of sars-cov-2 mrna domain vaccines |
WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
WO2022204370A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
AU2022249357A1 (en) | 2021-04-01 | 2023-10-12 | Modernatx, Inc. | Methods for identification and ratio determination of rna species in multivalent rna compositions |
JP2024514182A (ja) | 2021-04-13 | 2024-03-28 | モデルナティエックス インコーポレイテッド | 呼吸器ウイルス組み合わせワクチン |
WO2022221440A1 (en) | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
WO2022246020A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
WO2022266083A2 (en) | 2021-06-15 | 2022-12-22 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
WO2022266389A1 (en) | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Alternative rna purification strategies |
WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
WO2023287751A1 (en) | 2021-07-12 | 2023-01-19 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
WO2023009499A1 (en) | 2021-07-27 | 2023-02-02 | Modernatx, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a) |
TW202321446A (zh) | 2021-08-13 | 2023-06-01 | 美商現代公司 | 多管柱層析mRNA純化 |
CN115216483B (zh) * | 2021-08-30 | 2024-01-23 | 中国科学院遗传与发育生物学研究所 | poly(A)尾巴非A修饰在促进mRNA翻译中的应用 |
WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
WO2023064469A1 (en) | 2021-10-13 | 2023-04-20 | Modernatx, Inc. | Compositions of mrna-encoded il15 fusion proteins and methods of use thereof |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
WO2023077170A1 (en) | 2021-11-01 | 2023-05-04 | Modernatx, Inc. | Polynucleotides encoding integrin beta-6 and methods of use thereof |
WO2023076658A1 (en) | 2021-11-01 | 2023-05-04 | Modernatx, Inc. | Mass spectrometry of mrna |
WO2023081311A1 (en) | 2021-11-05 | 2023-05-11 | Modernatx, Inc. | Methods of purifying dna for gene synthesis |
WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023132885A1 (en) | 2022-01-04 | 2023-07-13 | Modernatx, Inc. | Methods of purifying dna for gene synthesis |
WO2023137149A1 (en) | 2022-01-14 | 2023-07-20 | Modernatx, Inc. | In vitro transcription dna purification and recycling |
WO2023141501A2 (en) * | 2022-01-19 | 2023-07-27 | Virginia Tech Intellectual Properties, Inc. | Nudix overexpressing engineered plants and uses thereof |
WO2023150256A1 (en) | 2022-02-03 | 2023-08-10 | Modernatx, Inc. | Continuous precipitation for mrna purification |
WO2023159197A1 (en) | 2022-02-18 | 2023-08-24 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
WO2023201296A1 (en) | 2022-04-15 | 2023-10-19 | Modernatx, Inc. | Ribosomal engagement potency assay |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023230481A1 (en) | 2022-05-24 | 2023-11-30 | Modernatx, Inc. | Orthopoxvirus vaccines |
WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
WO2024010993A1 (en) | 2022-07-06 | 2024-01-11 | Modernatx, Inc. | Primer design for cell-free dna production |
WO2024015890A1 (en) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
WO2024050483A1 (en) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
WO2024097874A1 (en) | 2022-11-03 | 2024-05-10 | Modernatx, Inc. | Chemical stability of mrna |
WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5824497A (en) * | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
JP4108126B2 (ja) | 1996-04-26 | 2008-06-25 | リュクスウニヴェルシテート テ レイデン | T細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン |
DE69738719D1 (de) | 1996-09-13 | 2008-07-03 | Lipoxen Technologies Ltd | Liposome |
EP0839912A1 (de) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
WO1999014346A2 (en) | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | SENSE mRNA THERAPY |
JP2001522603A (ja) | 1997-11-06 | 2001-11-20 | ロシュ ダイアグノスティックス ゲーエムベーハー | 腫瘍特異的抗原、その製造方法、ならびに免疫および診断のためのその使用 |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
WO2000020029A1 (en) | 1998-10-05 | 2000-04-13 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
SG143935A1 (en) | 1999-05-06 | 2008-07-29 | Univ Wake Forest | Compositions and methods for identifying antigens which elicit an immune response |
AU4903101A (en) | 1999-11-30 | 2001-07-09 | Cornell Research Foundation Inc. | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
CA2394748A1 (en) | 1999-12-28 | 2001-07-05 | Epimmune Inc. | Optimized minigenes and peptides encoded thereby |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
EP1292331A2 (de) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunstimulierende rns/dns hybridmolekule |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
DE60228212D1 (de) * | 2001-03-09 | 2008-09-25 | Gene Stream Pty Ltd | Neue expressionsvektoren |
GB0111015D0 (en) * | 2001-05-04 | 2001-06-27 | Norsk Hydro As | Genetic material |
EP1832603B1 (de) | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US7399753B2 (en) * | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
EP1361277A1 (de) * | 2002-04-30 | 2003-11-12 | Centre National De La Recherche Scientifique (Cnrs) | Optimierung von Transgenexpression in Säugetierzellen |
ES2329461T3 (es) | 2002-06-13 | 2009-11-26 | Merck Patent Gmbh | Procedimiento para la identificacion de alo-antigenos y su empleo para la terapia del cancer y en el transplante. |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
EP2286794B8 (de) | 2003-10-15 | 2016-06-01 | SynCore Biotechnology CO., LTD | Verwendung von kationischen liposomen mit paclitacel |
DE602004030369D1 (de) | 2003-10-24 | 2011-01-13 | Immunaid Pty Ltd | Therapieverfahren |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
WO2006071990A2 (en) | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
EP2418278A3 (de) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
EP1762575A1 (de) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie |
EP1994181A4 (de) | 2006-02-27 | 2010-05-19 | Univ Arizona | Identifizierung und verwendung von novopeptiden zur behandlung von krebs |
AU2007342338A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
AU2007339897B2 (en) | 2006-12-27 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of infections and tumors |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
EP3222634A1 (de) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antikörper zum humanen programmierten zelltod-pd-1-rezeptor |
EP2060583A1 (de) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identifikation Tumor-assoziierter Marker für Diagnose und Therapie |
EP2276486B1 (de) | 2008-03-24 | 2013-08-28 | 4SC Discovery GmbH | Neue substituierte imidazochinoline |
CN110075113A (zh) | 2008-04-17 | 2019-08-02 | Pds生物科技公司 | 通过阳离子脂质的对映体刺激免疫应答 |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
CN105255881A (zh) | 2009-07-31 | 2016-01-20 | 埃泽瑞斯公司 | 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna |
WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
AU2011252795B2 (en) | 2010-05-14 | 2015-09-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
EP2625189B1 (de) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Manipulierte nukleinsäuren und anwendungsverfahren dafür |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
US20150030576A1 (en) | 2012-01-10 | 2015-01-29 | Moderna Therapeutics, Inc. | Methods and compositions for targeting agents into and across the blood-brain barrier |
ES2572606T3 (es) | 2012-02-20 | 2016-06-01 | Universita' Degli Studi Di Milano | Compuestos miméticos de Smac homo y heterodímeros como inductores de apoptosis |
US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
AU2013243947A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
WO2013152220A2 (en) * | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
MX364370B (es) | 2012-07-12 | 2019-04-24 | Persimmune Inc | Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas. |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
JP6510416B2 (ja) | 2012-11-01 | 2019-05-08 | ファクター バイオサイエンス インコーポレイテッド | 細胞中でタンパク質を発現するための方法および生成物 |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2971010B1 (de) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
EP2983702A2 (de) | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Zusammensetzungen und verfahren für personalisierte neoplasieimpfstoffe |
WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3043826A4 (de) | 2013-09-13 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynukleotidzusammensetzungen mit aminosäuren |
JP6363179B2 (ja) | 2013-09-26 | 2018-07-25 | バイオンテック アーゲー | Rnaによるシェルを含む粒子 |
EP3052479A4 (de) | 2013-10-02 | 2017-10-25 | Moderna Therapeutics, Inc. | Polynukleotidmoleküle und verwendungen davon |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
EP3076994A4 (de) | 2013-12-06 | 2017-06-07 | Modernatx, Inc. | Gerichtete adaptive impfstoffe |
EP3053585A1 (de) | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Alternative nukleinsäuremoleküle und verwendungen davon |
AU2014381849A1 (en) | 2014-02-05 | 2016-08-25 | Biontech Ag | A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
PT4023755T (pt) | 2014-12-12 | 2023-07-05 | CureVac SE | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
EP3494982A1 (de) | 2014-12-30 | 2019-06-12 | CureVac AG | Künstliche nukleinsäuremoleküle |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
-
2005
- 2005-09-28 DE DE102005046490A patent/DE102005046490A1/de not_active Ceased
-
2006
- 2006-09-28 WO PCT/EP2006/009448 patent/WO2007036366A2/de active Application Filing
- 2006-09-28 US US11/992,638 patent/US9476055B2/en active Active
- 2006-09-28 PL PL10014763T patent/PL2357230T3/pl unknown
- 2006-09-28 CA CA2621444A patent/CA2621444C/en active Active
- 2006-09-28 ES ES10014763.6T patent/ES2467678T3/es active Active
- 2006-09-28 AT AT06805937T patent/ATE550427T1/de active
- 2006-09-28 JP JP2008532678A patent/JP5435949B2/ja active Active
- 2006-09-28 AU AU2006296702A patent/AU2006296702B2/en active Active
- 2006-09-28 RS RS20120238A patent/RS52353B/en unknown
- 2006-09-28 SI SI200631340T patent/SI1934345T1/sl unknown
- 2006-09-28 ES ES06805937T patent/ES2384113T3/es active Active
- 2006-09-28 PT PT06805937T patent/PT1934345E/pt unknown
- 2006-09-28 SI SI200631790T patent/SI2357230T1/sl unknown
- 2006-09-28 IN IN2116CHN2014 patent/IN2014CN02116A/en unknown
- 2006-09-28 EP EP10014763.6A patent/EP2357230B1/de active Active
- 2006-09-28 DK DK10014763.6T patent/DK2357230T3/da active
- 2006-09-28 RS RS20140311A patent/RS53351B/en unknown
- 2006-09-28 CA CA3023101A patent/CA3023101C/en active Active
- 2006-09-28 EP EP06805937A patent/EP1934345B9/de active Active
- 2006-09-28 DK DK06805937.7T patent/DK1934345T3/da active
- 2006-09-28 PL PL06805937T patent/PL1934345T3/pl unknown
- 2006-09-28 PT PT100147636T patent/PT2357230E/pt unknown
-
2011
- 2011-09-12 HK HK11109616.2A patent/HK1155477A1/xx unknown
-
2012
- 2012-06-06 CY CY20121100514T patent/CY1113526T1/el unknown
- 2012-06-08 HR HRP20120480TT patent/HRP20120480T1/hr unknown
- 2012-07-10 JP JP2012154852A patent/JP6058928B2/ja active Active
-
2014
- 2014-06-12 HR HRP20140561TT patent/HRP20140561T1/hr unknown
- 2014-07-02 CY CY20141100498T patent/CY1115246T1/el unknown
-
2015
- 2015-09-10 JP JP2015178829A patent/JP2016027811A/ja active Pending
-
2016
- 2016-07-22 US US15/217,555 patent/US10106800B2/en active Active
-
2018
- 2018-09-27 US US16/143,520 patent/US20190062762A1/en active Pending
-
2022
- 2022-10-25 US US18/049,593 patent/US20230193296A1/en active Pending
Non-Patent Citations (1)
Title |
---|
None |
Cited By (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10414824B2 (en) | 2002-11-22 | 2019-09-17 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
US9486519B2 (en) | 2008-12-10 | 2016-11-08 | Biontech Ag | Use of FLT3 ligand for enhancing immune responses in RNA immunization |
JP2012523231A (ja) * | 2009-04-10 | 2012-10-04 | オブシェストヴォ エス オグラニヒェンノイ オトヴェツトヴェンノストユ “ラボラトリア クレトフニクフ テクノロギイ” | 多能性幹細胞の製造方法 |
US9295717B2 (en) | 2009-08-05 | 2016-03-29 | Biontech Ag | Vaccine composition comprising 5′-cap modified RNA |
EP2281579A1 (de) | 2009-08-05 | 2011-02-09 | BioNTech AG | Impfstoffzusammensetzung mit 5'-Cap-modifizierter RNA |
WO2011015347A1 (en) | 2009-08-05 | 2011-02-10 | Biontech Ag | Vaccine composition comprising 5'-cap modified rna |
US11666534B2 (en) | 2010-07-06 | 2023-06-06 | Glaxosmithkline Biologicals Sa | Methods of administering lipid formulations with viral immunogens |
US11759475B2 (en) | 2010-07-06 | 2023-09-19 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11891608B2 (en) | 2010-07-06 | 2024-02-06 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
US11883534B2 (en) | 2010-07-06 | 2024-01-30 | Glaxosmithkline Biologicals Sa | Immunisation with lipid formulations with RNA encoding immunogens |
US11865080B2 (en) | 2010-07-06 | 2024-01-09 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11857562B2 (en) | 2010-07-06 | 2024-01-02 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11857681B2 (en) | 2010-07-06 | 2024-01-02 | Glaxosmithkline Biologicals Sa | Lipid formulations with RNA encoding immunogens |
US11839686B2 (en) | 2010-07-06 | 2023-12-12 | Glaxosmithkline Biologicals Sa | Lipid formulations with viral immunogens |
US11786467B2 (en) | 2010-07-06 | 2023-10-17 | Glaxosmithkline Biologicals Sa | Lipid formulations with immunogens |
US11773395B1 (en) | 2010-07-06 | 2023-10-03 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
US11766401B2 (en) | 2010-07-06 | 2023-09-26 | Glaxosmithkline Biologicals Sa | Methods of administering lipid formulations with immunogens |
US20220125723A1 (en) | 2010-07-06 | 2022-04-28 | Glaxosmithkline Biologicals Sa | Lipid formulations with viral immunogens |
US11596645B2 (en) | 2010-07-06 | 2023-03-07 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690865B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11638693B2 (en) | 2010-07-06 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids |
US11739334B2 (en) | 2010-07-06 | 2023-08-29 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11905514B2 (en) | 2010-07-06 | 2024-02-20 | Glaxosmithkline Biological Sa | Immunisation of large mammals with low doses of RNA |
US11638694B2 (en) | 2010-07-06 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens |
US11730754B2 (en) | 2010-07-06 | 2023-08-22 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11913001B2 (en) | 2010-07-06 | 2024-02-27 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11717529B2 (en) | 2010-07-06 | 2023-08-08 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11707482B2 (en) | 2010-07-06 | 2023-07-25 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11655475B2 (en) | 2010-07-06 | 2023-05-23 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
US11696923B2 (en) | 2010-07-06 | 2023-07-11 | Glaxosmithkline Biologicals, Sa | Delivery of RNA to trigger multiple immune pathways |
US11690861B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690862B1 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690864B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US11690863B2 (en) | 2010-07-06 | 2023-07-04 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2796557A1 (de) | 2010-08-13 | 2014-10-29 | CureVac GmbH | Nucleinsäure mit oder zur Codierung einer Histon-Haarnadelstruktur und poly(A)-Sequenz oder ein Polyadenylationssignal zur Erhöhung der Expression eines codierten Proteins |
WO2012019780A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
US11759422B2 (en) | 2010-08-31 | 2023-09-19 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding RNA |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US11639370B2 (en) | 2010-10-11 | 2023-05-02 | Glaxosmithkline Biologicals Sa | Antigen delivery platforms |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US11248264B2 (en) | 2011-05-24 | 2022-02-15 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
US10738355B2 (en) | 2011-05-24 | 2020-08-11 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
EP3404103A1 (de) | 2012-02-15 | 2018-11-21 | CureVac AG | Nucleinsäure, enthaltend eine oder codierend für eine histon-stammschleife und eine poly(a)-sequenz oder ein polyadenylierungssignal zur erhöhung der expression eines codierten allergen-antigens oder eines autoimmunen selbstantigens |
EP3178488A1 (de) | 2012-02-15 | 2017-06-14 | CureVac AG | Nucleinsäure mit oder zur codierung einer histon-haarnadelstruktur und poly(a)-sequenz oder ein polyadenylationssignal zur erhöhung der expression eines codierten tumorantigens |
WO2013120627A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120626A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120628A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120629A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
EP3348645A1 (de) | 2012-02-15 | 2018-07-18 | CureVac AG | Nukleinsäure mit einer histon-stammschleife und einer poly(a)-sequenz oder zu deren codierung oder polyadenylierungssignal zur erhöhung der expression eines codierten pathogenen antigens |
EP3527662A1 (de) | 2012-02-15 | 2019-08-21 | CureVac AG | Nukleinsäure mit oder zur codierung einer histon-haarnadelstruktur und poly(a)-sequenz oder ein polyadenylationssignal zur erhöhung der expression eines codierten tumorantigens |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
EP3741859A1 (de) | 2012-02-15 | 2020-11-25 | CureVac AG | Nucleinsäure mit oder zur codierung einer histon-haarnadelstruktur und einer poly(a)-sequenz oder eines polyadenylationssignals eines codierten therapeutischen proteins |
EP3348644A1 (de) | 2012-02-15 | 2018-07-18 | CureVac AG | Nukleinsäure mit oder zur codierung einer histon-haarnadelstruktur und poly(a)-sequenz oder ein polyadenylationssignal zur erhöhung der expression eines codierten tumorantigens |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013151668A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of secreted proteins |
WO2013151666A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
WO2013151736A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | In vivo production of proteins |
EP3501550A1 (de) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
EP3978030A1 (de) | 2012-04-02 | 2022-04-06 | ModernaTX, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US10093736B2 (en) | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
EP3766903A2 (de) | 2012-11-13 | 2021-01-20 | BioNTech SE | Bispezifischer antikörper anti claudin xcd3 zur behandlung von krebserkrankungen mit claudin-expression |
US11504419B2 (en) | 2012-11-28 | 2022-11-22 | BioNTech SE | Individualized vaccines for cancer |
US10155031B2 (en) | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015095351A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
US10717982B2 (en) | 2014-07-11 | 2020-07-21 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(A) sequence encoding DNA sequences |
EP4159741A1 (de) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Verfahren zur herstellung eines chimären polynukleotids zur kodierung eines polypeptids mit einer triazolhaltigen internukleotid-bindung |
WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US11400169B2 (en) | 2014-10-09 | 2022-08-02 | Seattle Children's Hospital | Long poly(A) plasmids and methods for introduction of long poly(A) sequences into the plasmid |
EP4023755A1 (de) * | 2014-12-12 | 2022-07-06 | CureVac AG | Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression |
US11761009B2 (en) | 2014-12-12 | 2023-09-19 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
US11149278B2 (en) | 2014-12-12 | 2021-10-19 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
WO2016091391A1 (en) * | 2014-12-12 | 2016-06-16 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
EP4023755B1 (de) | 2014-12-12 | 2023-04-26 | CureVac SE | Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression |
EP3230458B1 (de) * | 2014-12-12 | 2020-02-19 | CureVac AG | Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression |
EP3708668A1 (de) * | 2014-12-12 | 2020-09-16 | CureVac AG | Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression |
US11286492B2 (en) | 2014-12-12 | 2022-03-29 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
US11345920B2 (en) | 2014-12-12 | 2022-05-31 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
EP3708668B1 (de) | 2014-12-12 | 2022-07-27 | CureVac AG | Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression |
EP4241784A3 (de) * | 2014-12-12 | 2023-11-15 | CureVac SE | Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression |
EP4155409A1 (de) * | 2015-08-10 | 2023-03-29 | CureVac Real Estate GmbH | Verfahren zur erhöhung der replikation eines zirkulären dna-moleküls |
EP3334828B1 (de) | 2015-08-10 | 2020-10-28 | CureVac Real Estate GmbH | Verfahren zur erhöhung der replikation eines zirkulären dna-moleküls |
CN108291230B (zh) * | 2015-10-07 | 2022-12-20 | 生物技术公司 | 用于使rna稳定的3’utr序列 |
CN108291230A (zh) * | 2015-10-07 | 2018-07-17 | 生物技术Rna制药有限公司 | 用于使rna稳定的3’utr序列 |
US11492628B2 (en) | 2015-10-07 | 2022-11-08 | BioNTech SE | 3′-UTR sequences for stabilization of RNA |
JP2021048847A (ja) * | 2015-10-07 | 2021-04-01 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh | Rnaの安定化のための3’utr配列 |
WO2017060314A3 (en) * | 2015-10-07 | 2017-05-18 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
EP3636764A1 (de) * | 2015-10-07 | 2020-04-15 | BioNTech RNA Pharmaceuticals GmbH | 3'-utr-sequenzen zur stabilisierung von rna |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
EP3868885A1 (de) * | 2015-10-07 | 2021-08-25 | BioNTech RNA Pharmaceuticals GmbH | 3'-utr-sequenzen zur stabilisierung von rna |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
WO2017182524A1 (en) | 2016-04-22 | 2017-10-26 | Biontech Rna Pharmaceuticals Gmbh | Methods for providing single-stranded rna |
WO2017182634A1 (en) | 2016-04-22 | 2017-10-26 | Curevac Ag | Rna encoding a tumor antigen |
EP3777881A1 (de) | 2016-04-22 | 2021-02-17 | CureVac AG | Für ein tumor-antigen codierende rns |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
WO2017201350A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
WO2019175356A1 (en) | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
WO2020127532A2 (en) | 2018-12-19 | 2020-06-25 | Versameb Ag | Rna encoding a protein |
WO2021008708A1 (en) | 2019-07-18 | 2021-01-21 | Biontech Rna Pharmaceuticals Gmbh | Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles |
WO2021009368A1 (en) | 2019-07-18 | 2021-01-21 | Biontech Rna Pharmaceuticals Gmbh | Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles |
WO2021160346A1 (en) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
US11951185B2 (en) | 2020-04-22 | 2024-04-09 | BioNTech SE | RNA constructs and uses thereof |
WO2022016125A1 (en) | 2020-07-17 | 2022-01-20 | Genentech, Inc. | Attention-based neural network to predict peptide binding, presentation, and immunogenicity |
WO2022101486A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
WO2022101470A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
WO2022101471A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Pharmaceutical compositions comprising lipid nanoparticles and mrna, and methods for preparing and storing the same |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022162027A3 (en) * | 2021-01-27 | 2022-11-03 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022218891A2 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
WO2022218503A1 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
WO2022228827A1 (en) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
WO2022235847A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Technologies for early detection of variants of interest |
WO2023006920A1 (en) | 2021-07-29 | 2023-02-02 | BioNTech SE | Compositions and methods for treatment of melanoma |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023031367A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023036960A1 (en) | 2021-09-10 | 2023-03-16 | BioNTech SE | Lipid-based rna formulations suitable for therapy |
WO2023052531A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
EP4169578A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
EP4238577A2 (de) | 2021-10-22 | 2023-09-06 | BioNTech SE | Zusammensetzungen zur verabreichung verschiedener dosen von rna |
EP4169534A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
EP4169579A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfid-oligosaccharid-verbindungen und -komplexe |
EP4169580A1 (de) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023073190A1 (en) | 2021-10-28 | 2023-05-04 | BioNTech SE | Rna constructs and uses thereof |
WO2023083916A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
EP4186528A1 (de) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023126404A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023148277A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery of nucleic acids to cells |
WO2023148276A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery to cells |
WO2023166099A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | RNA LIPID NANOPARTICLES (LNPs) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE POLYMER |
WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
WO2023194508A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising a multivalent anion, such as an inorganic polyphosphate, and methods for preparing, storing and using the same |
EP4286004A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfid-oligosaccharid-verbindungen und -komplexe |
EP4285933A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
EP4286003A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
EP4285932A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidkomplexe und verwendungen |
EP4286394A1 (de) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharidverbindungen und -komplexe |
WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024028325A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024064886A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Using n-terminal degrons to enhance rna t cell vaccine immunogenicity |
WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1934345B1 (de) | Modifikationen von rna, die zu einer erhöhten transkriptstabilität und translationseffizienz führen | |
DE60038011T2 (de) | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie | |
EP1832603B1 (de) | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung | |
EP1776460B1 (de) | Verfahren zur modulation der genexpression durch änderung des cpg gehalts | |
DE202015010020U1 (de) | Stabilisierung von für Poly (A) -Sequenzen kodierende DNA-Sequenzen | |
DE102008061522A1 (de) | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung | |
DE69333953T2 (de) | Promotor des transaldolase-genes von k.lactis und dessen verwendung | |
AU2011253592B2 (en) | Modification of RNA, producing an increased transcript stability and translation efficiency | |
DE3819463A1 (de) | Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen | |
DE69735535T2 (de) | Genexpression in monocyten und makrophagen | |
DE102004037652B4 (de) | Verfahren zur Modulation der Genexpression durch Änderung des CpG Gehalts | |
DD298269A5 (de) | Verfahren zur herstellung von fremdproteinen in tierischen zellen | |
DE4021917A1 (de) | Glykosyliertes ifnalpha | |
DE10326189A1 (de) | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe | |
EP1167529A2 (de) | Vektorsystem zum Einbringen von DNA in eukaryonte Zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2621444 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006805937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006296702 Country of ref document: AU Ref document number: 1490/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008532678 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006296702 Country of ref document: AU Date of ref document: 20060928 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006296702 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006805937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11992638 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2012/0238 Country of ref document: RS |